Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Newly Diagnosed Malignant Glioma Trials

CDX110-04: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

Principal Investigator: Pamela New, M.D.
Sub-Investigator: David Baskin, M.D., Jonathon Zhang, M.D., Suzanne Powell, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this study is find out whether adding treatment with an investigational vaccine, rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug called temozolomide helps to shrink brain tumors or prevents brain tumors from growing when compared to treatment with temozolomide alone.
Status: Active  

Ask a question or refer a patient.

NWBT 020221: A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

Principal Investigator: Pamela New, M.D., David Baskin, M.D.
Sub-Investigator: Jonathon Zhang, M.D., Suzanne Powell, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: This study uses the participant's own dendritic cells which act as messengers to alert the immune system to tumor cells, to target the proteins specific to the patient’s tumor. In other words this personalized vaccine activates the system to recognize and destroy brain tumor cells. Participants who are interested in enrolling in this clinical trial need to meet specific eligibility requirements which include:

  • Surgery at Houston Methodist Hospital

  • This is a placebo-controlled study, with two patients out of three receiving standard of care plus the active DCVax vaccine investigational treatment. One out of three will receive standard of care treatment, plus an inactive placebo. However if participants on placebo therapy have any signs of disease progression, they will have the option to cross over to active vaccine investigational treatment.

Your doctor will be able to review with you these and other eligibility criteria.
Status: Active

Ask a question or refer a patient.

NovoCure EF-14: A Prospective, Multi-Center Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM (IRB: 0310-0048) – NovoCure Ltd. Trial

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this study is to determine if the addition of a device called NovoTTF-100A given with standard chemotherapy drug called Temozolomide (Temodar) is more effective than when Temozolomide is given alone. The NovoTTF-100A device is a portable battery operated device which produces Tumor Treating Fields (TTFields) within the human body through surface electrodes. It is believed that with very low intensity, intermediate frequency electric fields (TTFields) will stunt the growth of tumor cells.
Status: Active

Ask a question or refer a patient.

RTOG 0834: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The CATNON Intergroup Trial

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: This is a phase III trial to assess the safety and efficacy of daily concurrent/adjuvant temozolomide improves the overall survival as compared to no daily/no adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma and its progression free survival.
Status: Active

Ask a question or refer a patient.

COGLI Trial: Phase I/II Administration of CMV-specific cytotoxic T cells in patients with Glioblastoma multiforme: Cell and Gene Therapy Trial

Principal Investigators: Stephen Gottschalk, M.D. & Pamela New, M.D., Nabil Ahmed, M.D, Robert Grossman, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this study is to find the largest safe dose of CMV-T cells using patient's own Immune cells, to learn what the side effects are, and to see whether this therapy might help patients with Gliomblastoma. CMV is found in the majority of Glioblastomas and thus serves as an attractive target for cellular therapies.
Status: Active

Ask a question or refer a patient.

?
How Can We Help?
Call us